PTEN and neoplasm: Using PCa mouse models with PTEN mutations followed by RB1 loss, Ku et al. [26] showed that PTEN and RB1 serve as lineage plasticity markers that enhance tumor metastasis, while the additional loss of tumor suppressor TP53 allows tumors to resist antiandrogen therapy.